371 related articles for article (PubMed ID: 15577030)
1. [K/DOQI clinical practice guidelines for management of renal osteodystrophy in predialysis patients].
Okada N; Tsubakihara Y
Clin Calcium; 2004 May; 14(5):698-706. PubMed ID: 15577030
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
Coburn JW; Elangovan L
J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
[TBL] [Abstract][Full Text] [Related]
4. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
5. [Vitamin D therapy in predialysis renal failure].
Ando R
Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
Hoshino J; Ubara Y; Takaichi K
Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
[TBL] [Abstract][Full Text] [Related]
7. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
8. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
Górriz JL; Molina P; Bover J; Barril G; Martín-de Francisco AL; Caravaca F; Hervás J; Piñera C; Escudero V; Molinero LM;
Nefrologia; 2013 Jan; 33(1):46-60. PubMed ID: 23364626
[TBL] [Abstract][Full Text] [Related]
10. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
Zisman AL; Hristova M; Ho LT; Sprague SM
Am J Nephrol; 2007; 27(1):36-43. PubMed ID: 17215573
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Control of parathyroid function in patients with a short history of hemodialysis.
Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
[TBL] [Abstract][Full Text] [Related]
13. [The medical treatment strategy of secondary hyperparathyroidism use of vitamin D in Europe and America].
Miwa N; Akiba T
Clin Calcium; 2004 Sep; 14(9):57-9. PubMed ID: 15577111
[TBL] [Abstract][Full Text] [Related]
14. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
Morio K; Koide K
Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
[TBL] [Abstract][Full Text] [Related]
16. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone and biochemical profile in chronic kidney disease patients in South India.
Sankarasubbaiyan S; Abraham G; Soundararajan P; Chandrasekaran V; Padma G
Hemodial Int; 2005 Jan; 9(1):63-7. PubMed ID: 16191055
[TBL] [Abstract][Full Text] [Related]
18. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
19. Guideline-practice gap in the management of predialysis chronic kidney disease mineral bone disorder in Japan.
Hamano T; Fujii N; Matsui I; Nakano C; Inoue K; Tomida K; Mikami S; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
Ther Apher Dial; 2011 Jun; 15 Suppl 1():2-8. PubMed ID: 21595844
[TBL] [Abstract][Full Text] [Related]
20. [Guideline for the management of chronic kidney disease-related mineral and bone disorders (CKD-MBD)].
Kakuta T
Clin Calcium; 2007 May; 17(5):752-9. PubMed ID: 17471006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
